KMI/PAREXEL FORMS ALLIANCE WITH LEARNWRIGHT
BOSTON, MA, September 2, 2003 — KMI/PAREXEL, an operating unit of PAREXEL International Corporation, (Nasdaq: PRXL), is pleased to announce formation of a strategic alliance with Learnwright, Inc., an e-learning solutions provider headquartered in Rockville, Maryland. The goal of the alliance is to co-develop e-learning solutions covering current Good Manufacturing Practices (cGMP) for the highly regulated pharmaceutical, medical device and biotechnology industries.
Under the agreement, the combination of KMI/PAREXEL’s knowledge of the pharmaceutical, biopharmaceutical and medical device industries with Learnwright’s web-enabled, e-learning applications will provide leading manufacturers with a single source for implementing e-learning in FDA-regulated environments. The combined efforts can help customers accelerate the deployment of e-learning solutions and improve compliance effectiveness across the enterprise. Learnwright’s offerings include online educational tools to assist pharmaceutical, biotechnology, and medical device companies in developing a high performance cGMP workforce. Projects performed by the collaboration will provide compliance and technology expertise, and include multi-media, web-based instructional courseware to serve the global cGMP environment.
“By collaborating with Learnwright, KMI/PAREXEL will co-develop e-learning programs, and assist with deployment of e-learning solutions for leading manufacturers worldwide,” stated Ronald F. Tetzlaff, Ph.D., President, KMI/PAREXEL. “Subsequently, manufacturers will be able to ensure high-quality, consistent standards of employee training, even across international boundaries. ”
KMI/PAREXEL helps clients maximize their compliance effectiveness by integrating strategic planning, auditing, and training with the design of standard-compliant quality systems, implementation of information technology solutions, and validation of manufacturing processes. Its consultants include industry experts and former regulatory officials with a wide range of experience in helping clients understand and meet the regulatory challenges of today's global operations. KMI/PAREXEL, headquartered in Waltham, MA, is an operating unit of PAREXEL International Corporation’s PAREXEL Consulting Group. PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of expertise in clinical research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries.
Learnwright is a software company that creates and delivers multimedia training programs to companies that operate in the pharmaceutical industries. Their technology allows companies to provide high-quality,
interactive training to personnel in multiple and distant locations, via intranets or the Internet, while improving outcomes. Additional information about Learnwright and its courseware is available at www.learnwright.com.
This release contains "forward-looking" statements. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects" and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of Amendment No. 2 to the Company's Registration Statement on Form S-3/A, as filed with the Securities and Exchange Commission on July 15, 2003, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.